Literature DB >> 20211896

Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis.

Hiroki Ando1, Yuji Kondo, Toshinori Suetake, Emiko Toyota, Seiya Kato, Toru Mori, Teruo Kirikae.   

Abstract

Isoniazid (INH) is an effective first-line antituberculosis drug. KatG, a catalase-peroxidase, converts INH to an active form in Mycobacterium tuberculosis, and katG mutations are major causes of INH resistance. In the present study, we sequenced katG of 108 INH-resistant M. tuberculosis clinical isolates. Consequently, 9 novel KatG mutants with a single-amino-acid substitution were found. All of these mutants had significantly lower INH oxidase activities than the wild type, and each mutant showed various levels of activity. Isolates having mutations with relatively low activities showed high-level INH resistance. On the basis of our results and known mutations associated with INH resistance, we developed a new hybridization-based line probe assay for rapid detection of INH-resistant M. tuberculosis isolates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211896      PMCID: PMC2863633          DOI: 10.1128/AAC.01691-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore.

Authors:  A S Lee; I H Lim; L L Tang; A Telenti; S Y Wong
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil.

Authors:  Rosilene Fressatti Cardoso; Robert C Cooksey; Glenn P Morlock; Patricia Barco; Leticia Cecon; Francisco Forestiero; Clarice Q F Leite; Daisy N Sato; Maria de Lourdes Shikama; Elsa M Mamizuka; Rosario D C Hirata; Mario H Hirata
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia.

Authors:  H J Marttila; H Soini; E Eerola; E Vyshnevskaya; B I Vyshnevskiy; T F Otten; A V Vasilyef; M K Viljanen
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990 to 1997).

Authors:  Z Fang; C Doig; A Rayner; D T Kenna; B Watt; K J Forbes
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

5.  Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands.

Authors:  H R van Doorn; P E W de Haas; K Kremer; C M J E Vandenbroucke-Grauls; M W Borgdorff; D van Soolingen
Journal:  Clin Microbiol Infect       Date:  2006-08       Impact factor: 8.067

6.  Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan.

Authors:  H Ando; S Mitarai; Y Kondo; T Suetake; J-I Sekiguchi; S Kato; T Mori; T Kirikae
Journal:  Clin Microbiol Infect       Date:  2009-10-14       Impact factor: 8.067

7.  Crystal structure of Mycobacterium tuberculosis catalase-peroxidase.

Authors:  Thomas Bertrand; Nigel A J Eady; Jamie N Jones; Judit M Nagy; Brigitte Jamart-Grégoire; Emma Lloyd Raven; Katherine A Brown
Journal:  J Biol Chem       Date:  2004-07-01       Impact factor: 5.157

8.  Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production.

Authors:  Chih-Jen Wei; Benfang Lei; James M Musser; Shiao-Chun Tu
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Characterization of a trinucleotide repeat sequence (CGG)5 and potential use in restriction fragment length polymorphism typing of Mycobacterium tuberculosis.

Authors:  Yayoi Otsuka; Pawel Parniewski; Zofia Zwolska; Masatake Kai; Tomoko Fujino; Fumiko Kirikae; Emiko Toyota; Koichiro Kudo; Tadatoshi Kuratsuji; Teruo Kirikae
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

10.  High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone.

Authors:  Susanne Homolka; Erik Post; Barbara Oberhauser; Abu Garawani George; Lars Westman; Foday Dafae; Sabine Rüsch-Gerdes; Stefan Niemann
Journal:  BMC Microbiol       Date:  2008-06-25       Impact factor: 3.605

View more
  25 in total

Review 1.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

2.  Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Authors:  S B Georghiou; M Seifert; D Catanzaro; R S Garfein; F Valafar; V Crudu; C Rodrigues; T C Victor; A Catanzaro; T C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 3.  Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.

Authors:  Tomasz Jagielski; Alina Minias; Jakko van Ingen; Nalin Rastogi; Anna Brzostek; Anna Żaczek; Jarosław Dziadek
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

4.  Automated liquid culture system misses isoniazid heteroresistance in Mycobacterium tuberculosis isolates with mutations in the promoter region of the inhA gene.

Authors:  Z Zhang; J Lu; Y Wang; Y Pang; Y Zhao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-26       Impact factor: 3.267

5.  Comprehensive multicenter evaluation of a new line probe assay kit for identification of Mycobacterium species and detection of drug-resistant Mycobacterium tuberculosis.

Authors:  Satoshi Mitarai; Seiya Kato; Hideo Ogata; Akio Aono; Kinuyo Chikamatsu; Kazue Mizuno; Emiko Toyota; Akiko Sejimo; Katsuhiro Suzuki; Shiomi Yoshida; Takefumi Saito; Ataru Moriya; Akira Fujita; Shuko Sato; Tomoshige Matsumoto; Hiromi Ano; Toshinori Suetake; Yuji Kondo; Teruo Kirikae; Toru Mori
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

6.  Characterization of Large Deletion Mutants of Mycobacterium tuberculosis Selected for Isoniazid Resistance.

Authors:  Catherine Vilchèze; Rajagopalan Saranathan; Brian Weinrick; William R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

7.  Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China.

Authors:  Xiaoliang Yuan; Tiantuo Zhang; Kazuyoshi Kawakami; Jiaxin Zhu; Hongtao Li; Jianping Lei; Shaohua Tu
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

Review 8.  Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action.

Authors:  Saifur R Khan; Yousef Manialawy; Arno G Siraki
Journal:  Br J Pharmacol       Date:  2019-11-12       Impact factor: 8.739

9.  Evaluation of Anyplex™ II MTB/MDR kit's performance to rapidly detect isoniazid and rifampicin resistant Mycobacterium tuberculosis from various clinical specimens.

Authors:  Nuntana Chumpa; Kamon Kawkitinarong; Suwatchareeporn Rotcheewaphan; Ajcharaporn Sawatpanich; Suthidee Petsong; Somying Tumwasorn; Gompol Suwanpimolkul
Journal:  Mol Biol Rep       Date:  2020-03-02       Impact factor: 2.316

10.  Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes.

Authors:  Mai N T Huyen; Frank G J Cobelens; Tran N Buu; Nguyen T N Lan; Nguyen H Dung; Kristin Kremer; Edine W Tiemersma; Dick van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.